- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
| 08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 9 | Investing.com Deutsch | ||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 114 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 232 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 183 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
| 19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
| 19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.02. | Sera Prognostics dips 5%, prices $50M offering | 3 | Seeking Alpha | ||
| 10.02. | Sera Prognostics announces proposed public offering | 4 | Seeking Alpha | ||
| 10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 127 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 07.08.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 161 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,600 | +3,56 % | NanoRepro: Gute Kombination | Als NanoRepro im Oktober 2008 an die Börse ging, war der Namenszusatz "Nano" mächtig angesagt. Immerhin starteten zwischen 2005 und 2026 auch die Kapitalmarktstorys von NanoFocus, Nanostart, Nanogate... ► Artikel lesen | |
| OCUGEN | 0,942 | +0,94 % | Ocugen expands advisory board and leadership team for gene therapy push | ||
| VIKING THERAPEUTICS | 29,395 | +0,31 % | Viking Therapeutics nach Zahlen: Geht die Rallye weiter? | Seit meinem letzten Update läuft die Aktie von Viking Therapeutics immer höher. Die Rallye des Biotechs könnte sich nach dem Quartalsbericht von dieser Woche fortsetzen. Sektor erholt sich - Viking... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,260 | -3,55 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 7,332 | +0,63 % | RBC Capital: BioCryst-Aktie vor Quartalszahlen unterbewertet | ||
| VAXART | 0,361 | 0,00 % | Vaxart, Inc.: Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq | - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings... ► Artikel lesen | |
| IBIO | 0,610 | -1,61 % | XFRA DIVERSE ISINS: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,710 | -6,56 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,742 | +0,15 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,435 | +1,48 % | Cardiff Oncology vor Entscheidung: Die spannendste Krebs-Aktie! | Es ist der gewohnte Raketenstart nach Maß: Unser neuer Community-Tipp Cardiff Oncology legt furios los, gewinnt allein seit unserer Enthüllung im Live Chat vor genau einer Woche über 20% an Wert. Und... ► Artikel lesen | |
| ALDEYRA | 4,647 | +5,66 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MANNKIND | 3,482 | +0,84 % | MannKind stock price target lowered to $8 at RBC Capital on model updates | ||
| TRAWS PHARMA | 1,570 | -7,10 % | Traws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions | Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,860 | -2,38 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,040 (-1,22 %) liegt der Kurs bei 3,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.